UK: NICE Seeks Views On Using RWD To Inform Guidance
NICE, the health technology appraisal body for England and Wales, is consulting on greater use of real world data to develop guidance.
You may also be interested in...
Following NICE’s rejection last week for Tagrisso, AstraZeneca argues that the health technology appraisal body was wrong not to take the company’s real-world data into account when considering whether the lung cancer drug should be granted “end of life” status.
Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.
Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.